Ask about this productRelated genes to: SIRPG antibody
- Gene:
- SIRPG NIH gene
- Name:
- signal regulatory protein gamma
- Previous symbol:
- SIRPB2
- Synonyms:
- bA77C3.1, SIRP-B2, SIRPgamma, CD172g
- Chromosome:
- 20p13
- Locus Type:
- gene with protein product
- Date approved:
- 2001-09-17
- Date modifiied:
- 2016-01-20
Related products to: SIRPG antibody
Related articles to: SIRPG antibody
- The cluster of differentiation 47 (CD47)-signal regulatory protein α (SIRPα) axis plays crucial roles in tumour immune evasion, promoting tumorigenesis and malignancy progression. Preclinical studies have demonstrated that CD47 blockade synergises with anti-PD-1 therapy to enhance anti-tumour immunity. However, the functional mechanisms and therapeutic implications of this axis in hepatocellular carcinoma (HCC) remain insufficiently characterised. Our study employed a multi-omics approach integrating multiple layers-transcriptomic, mutational, immune and regulatory-to understand the functional roles of the CD47-SIRPα axis. Pan-cancer analyses of expression patterns and prognostic significance identified the CD47-SIRPα axis as a negative prognostic indicator in HCC, where the cellular heterogeneity of CD47 expression was mapped by its subcellular localisation patterns and somatic mutation profiles. Functional analyses revealed that high CD47 expression modulated cancer stemness and lipid metabolism in HCC. Furthermore, it remodeled the tumour immune micro-environment, characterised by modulating M1 macrophage polarization and elevated expression of immune checkpoints. The protein-protein interaction (PPI) network combined with structural bioinformatics analyses identified SIRPG and SIRPB1 as additional high-probability direct interaction partners of CD47. Biomarker relevance analysis showed that CD47 demonstrated predictive capacity in 15 cohorts, and drug sensitivity profiling identified epigenetic modulators and metabolic regulators as potential candidates for CD47-targeted combination therapy. Through expression profiling, correlation assessment and survival evaluation, we identified that the FGD5-AS1/miR-22-3p axis was the most potent upstream non-coding RNA regulatory pathway for CD47 in HCC. Our findings systematically characterise the CD47-SIRPα axis as a negative prognostic indicator and an immunotherapeutic target in HCC. - Source: PubMed
Publication date: 2026/01/24
Gao HuijieHu CuiminWu QingFang Zhong-Ze - SIRPG, a primate-specific type 1 transmembrane protein in the Signal Regulatory Protein (SIRP) family, is predominantly expressed in T cells. It contains a short cytoplasmic domain, which does not contain any known signaling motif, and its only known ligand is CD47. Several genetic variations in , including the V263A (rs6043409) polymorphism, linked to increased type 1 diabetes risk, highlight its potential importance. However, its expression and physiological role remain largely unclear due to its absence in rodents. Here, we demonstrate that SIRPG and GzmB exhibit near mutually exclusive expression in resting peripheral CD8+ T cells. We further show that SIRPG serves as a valuable marker for GzmK-expressing CD8+ T cells in peripheral blood and that its expression in both CD4+ and CD8+ T cells is upregulated by anti-CD3 stimulation, with further enhancement by the TNFα inhibitor adalimumab, but not certolizumab. While SIRPG ablation minimally affects T cell activation and IFNγ/TNFα production, it impairs the expression of mitosis-regulating genes like and , leading to reduced proliferation, and alters the expression of certain activation-induced surface molecules, including CRTAM. Notably, SIRPG-mediated proliferation and CRTAM expression are cell-autonomous and CD47-independent. Structural and functional analyses reveal that SIRPG-driven proliferation is independent of its extracellular D1 domain, not significantly affected by the V263 variant, but dependent on its cytoplasmic domain. Collectively, our findings offer novel insights into the expression, function, and mechanism of action of SIRPG in T cells. - Source: PubMed
Publication date: 2025/11/21
Marguerie FlavienSaifi Mohammad AGeary BenjaminBarnes DavidLim LauraJonsson Anna HelenaHo I-Cheng - Aberrant CD8 T-cell differentiation contributes to the pathogenesis of autoimmune diseases, and immune-mediated tissue damage. However, the molecular mechanisms that prevent premature effector T cell programming in humans remain incompletely defined. Signal regulatory protein gamma (SIRPγ) is selectively expressed on T-cells in the human immune system. Notably, genetic variants associated with reduced SIRPγ expression have been linked to increased risk of immune-mediated diseases, including type 1 diabetes and multiple sclerosis, but the contribution of SIRPγ to CD8 T-cell dysregulation in these contexts remains unclear. - Source: PubMed
Publication date: 2025/07/14
Morse MeganRodriguez XanthieDeLaRosa ErikaRodriguez SierraShanil JumaSinha Sushmita - SIRPG, a primate-specific type 1 transmembrane protein in the Signal Regulatory Protein (SIRP) family, is predominantly expressed in T cells. It contains a short cytoplasmic domain, which does not contain any known signaling motif, and its only known ligand is CD47. Several genetic variations in , including the V263A (rs6043409) polymorphism, linked to increased type 1 diabetes risk, highlight its potential importance. However, its expression and physiological role remain largely unclear due to its absence in rodents. Here, we demonstrate that SIRPG and GzmB exhibit near mutually exclusive expression in resting peripheral CD8+ T cells. We further show that SIRPG serves as a valuable marker for GzmK-expressing CD8+ T cells in peripheral blood and inflamed synovial fluid and that its expression in both CD4+ and CD8+ T cells is upregulated by anti-CD3 stimulation, with further enhancement by the TNFα inhibitor adalimumab, but not certolizumab. While SIRPG ablation minimally affects T cell activation and IFNγ/TNFα production, it impairs the expression of mitosis-regulating genes like and , leading to reduced proliferation, and alters the expression of certain activation-induced surface molecules, including CRTAM. Notably, SIRPG-mediated proliferation and CRTAM expression are cell-autonomous and CD47-independent. Structural and functional analyses reveal that SIRPG-driven proliferation is independent of its extracellular D1 domain, not significantly affected by the V263 variant, but dependent on its cytoplasmic domain. Collectively, our findings offer novel insights into the expression, function, and mechanism of action of SIRPG in T cells. - Source: PubMed
Publication date: 2025/05/07
Marguerie FlavienSaifi Mohammad AGeary BenjaminBarnes DavidJonsson Anna HHo I-Cheng - Endometrial cancer (EC) is one of the few malignancies with increasing incidence and mortality rates. Targeted therapy and immunotherapy have become pivotal treatment strategies for EC patients. However, the current methods and biomarkers for predicting immunotherapy responses and prognosis are remain limited. Programmed cell death (PCD) pathways play a crucial role in cancer development and progression and may serve as prognostic markers and indicators of drug sensitivity in EC. In our study, we integrated multiple PCD pathways and comprehensive multi-omics datasets from TCGA-EC and GEO databases. By analyzing distinct PCD signatures, we discovered two major EC subgroups with distinctive prognoses, tumor microenvironment (TME) profiles, and responses to immunotherapy. To further investigate the cellular basis of these PCD patterns, single-cell RNA sequencing analysis was conducted to explore tumor heterogeneity in PCD characteristics across EC subpopulations. Further investigation revealed seven key PCD-associated genes (HIF3A, ACTL8, SIRPG, FBN3, ARHGAP30, CD6, and P2RY13) that formed the basis for a novel prognostic scoring system-risk score (RS). Our findings showed that patients with lower risk scores had better survival rates and improved immunotherapy outcomes. Conversely, patients with higher risk scores experienced poor clinical outcomes and reduced immunotherapy efficacy, although alternative therapies such as docetaxel and olaparib demonstrated potential therapeutic benefits. Overall, the RS provides a valuable tool for early prognosis prediction and for identifying patients who may benefit from immunotherapy. - Source: PubMed
Publication date: 2025/07/01
Lu ShanWei YiyunChen LiuyanCheng JinlianQin LiuyanLu XuemeiPang Lihong